Forbion leads $26.5m round in Oxyrane

The round also included investments from Morningside Group and existing investor New Science Ventures.

The additional capital will be used to support Oxyrane through the preclinical research stage and the phase I and II of clinical RCTs for its Pompe disease treatment drug.

Company
Oxyrane is a biopharmaceutical company with headquarters in Manchester. The company develops enzyme replacement therapies (ERT). The primary focus are lysosomal storage diseases, which are a set of more than 40 rare inherited diseases.

Oxyrane operates with a proprietary platform to produce proteins with human sugar structures out of yeast Yarrowia lipolytica. The platform aims to outperform current commercial processes in terms of mannose 6-phosphate production (3-15 times as much).

Pome disease, a lysosomal storage disease, is an enzyme deficiency, which leads to nerve and muscle damage through glycogen accumulation.

People
Sander Slootweg, managing partner, led the deal on behalf of Forbion. He will join the board of Oxyrane alongside Dr. Gerald Chan of Morningside. Michael Campbell is CEO of Oxyrane. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Now researching
• Early-stage
• Healthcare